Background: This trial was designed to prove superiority of irinotecan over etoposide combined with carboplatin in extensive-disease small-cell lung cancer.
introduction Small-cell lung cancer (SCLC) accounts for 12%-15% of all lung cancer cases worldwide. It is characterized by a rapid tumor growth and an early hematogenous spread. At the time of presentation, more than two-thirds of patients present with extensive disease (ED), which is characterized by distant lymph node or organ metastases. Although response rates to first-line chemotherapy are relatively high, median survival is 8-10 months and 1-year survival rates are 30%-40% only.
Since decades, the combination of etoposide plus cis-or carboplatin has been the standard of care in extensive stage. Because carboplatin can more easily be administered and is equally effective in extensive stage [1, 2] , many European oncologists prefer carboplatin over cisplatin.
In 2001, first evidence for a superiority of irinotecan over etoposide in combination with cisplatin had been observed in the J9511 trial carried out by the Japanese Cooperative Oncology Group (JCOG) [3] . Their randomized phase III trial had been terminated early after accrual of 154 patients because an interim analysis showed a survival benefit in favor of irinotecan [3] .
Of four subsequent randomized phase III trials, only one confirmed superiority of irinotecan (see Table 1 ).
The Scandinavian phase III trial compared irinotecan 175 mg/m 2 i.v. on day 1 with oral etoposide 120 mg/m 2 /day on days 1-5 both in combination with carboplatin area under the curve (AUC) 4 (Chatelut's formula) on day 1 of a 3-week cycle.
Median survival was 8.5 and 7.1 months in the irinotecan and etoposide arms, respectively; thus, results of the J9511 trial were confirmed [4] . Quality-of-life analysis also favored the irinotecan arm. In contrast, two North American phase III studies published by Hanna et al. and by the South West Oncology Group (SWOG) failed to confirm a difference in overall survival (OS) or response rate when comparing irinotecan with etoposide in combination with cisplatin [5, 6] . SWOG S0124 trial had the same design as J9511 and included 645 patients. Irinotecan 60 mg/m 2 on days 1, 8, and 15 plus cisplatin 60 mg/m 2 on day 1 was administered every 4 weeks and compared with etoposide 100 mg/m 2 on days 1-3 plus cisplatin 80 mg/m 2 on day 1 every 3 weeks [6] .
One additional international phase III study also failed to confirm superiority of irinotecan over etoposide in combination with cisplatin. This trial randomly assigned 405 patients to receive cisplatin 80 mg/m 2 in combination with either irinotecan 65 mg/m 2 on days 1 and 8 or etoposide 100 mg/m 2 administered on days 1-3 every 3 weeks [7] . The results of all published phase III trials are summarized in Table 1 .
Based on the results of JCOG J9511 trial, we initiated this randomized phase III trial of the thoracic oncology group of the German Arbeitsgemeinschaft Internistische Onkologie (AIO) in 2001 to compare irinotecan with i.v. etoposide in combination with carboplatin. Maximum tolerated dose of carboplatin-irinotecan was previously defined in a dose escalation phase I trial [8] and used in this study. Etoposide 140 mg/m 2 i.v. on days 1-3 plus carboplatin AUC 5 on day 1 was administered in the standard treatment arm. This relatively high dose of etoposide was previously found to be the maximum tolerated dose [9] . Although usually etoposide 100-120 mg/m 2 is used in combination with cis-or carboplatin, we chose the higher dose to avoid suboptimal dosing in the standard therapy arm. The interim analysis at the phase II-III transition point after accrual of a total 70 patients demonstrated a response rate of 67% in the experimental arm and 59% in the standard arm and an acceptable toxicity in both arms; thus, criteria for extension into phase III were met [10] . Here, we report the final analysis of the randomized phase III trial.
patients and methods

patient selection
Patients with pathologically proven SCLC ED defined as malignant effusion or contralateral supraclavicular lymph node metastases or distant metastases were eligible. Staging procedure consisted of computed tomography (CT) scans of brain, chest, and abdomen. Inclusion criteria were as follows: no prior chemotherapy, life expectancy of >3 months, Karnofsky performance status ‡50%, measurable lesions, adequate hematologic function (leukocyte count >4000/mm 3 , platelet count >100 000/mm 3 ), and no severe hepatic or renal dysfunction with bilirubin level <1.25 · upper nornal limit (UNL) and creatinine level <1.25 · UNL. Criteria for exclusion were as follows: second active malignant disease, chronic diarrhea grade ‡1 [Common Toxicity Criteria (CTC)], chronic inflammatory bowel disease, severe cardiac dysfunction (New York Heart Association II or higher), pregnancy, lactation, inadequate contraception, and impaired mental status. All patients gave written informed consent. The trial was approved by the local ethics committee and registered at the National Cancer Institute (NCI): NCT00168896.
treatment plan
Arm A (IP) chemotherapy included irinotecan at a dose of 50 mg/m 2 administered on days 1, 8, and 15 in 250 ml NaCl 0.9% i.v. over 30 min. In arm B (EP), etoposide 140 mg/m 2 was administered on days 1, 2, and 3 in 1000 ml NaCl 0.9% i.v. over 90 min. Carboplatin was given in both treatment arms at a dose of AUC 5 mgÁmin/ml in 500 ml 5% glucose over 1 h on day 1. The individual dose of carboplatin was determined using Calvert's formula [11] : dose (mg) = AUC · [glomerular filtration rate (GFR) + 25]. GFR was determined using Jelliffe's formula [12] . Cycles were repeated on day 29 in arm A (IP) and on day 22 in arm B (EP). All patients received antiemetic therapy consisting of 5-HT 3 antagonist i.v., before starting the infusion of chemotherapy. In case of diarrhea, patients were instructed to take loperamide 4 mg, followed by 2 mg every 2 h until termination of diarrhea. efficacy and safety evaluations CT-based response evaluation according to the RECIST criteria published 2000 was carried out before initiation of chemotherapy and after two, four, and six cycles of chemotherapy. In the follow-up period, CT scans were carried out every 3 months. Toxicity was assessed clinically and by laboratory analysis once weekly.
trial design and statistical analysis
Randomization was stratified by center. A two-step design was chosen. In the first step, a total of 70 patients were randomly assigned, and response and stabilization rates were determined as the phase II end point. A response rate exceeding 50% in each arm and acceptable toxicity were the criteria for extension into the phase III section with simultaneous switch of the primary end point from response rate to progression-free survival (PFS). Results of the phase II step had been published earlier [10] . Secondary end points of the phase III study were response rate, OS, and toxicity. The number of patients included into the phase III trial was estimated as follows: based on an analysis using the two-sided log-rank test and the assumption that a maximum of 40% of patients in the standard arm (EP) were free of progression after 6 months and an increase to 60% in the experimental arm (IP) was judged to be clinically relevant, a total of 196 assessable patients were needed to determine this difference with an alpha error of 0.05 and a beta error of 0.2. Taking into account, a dropout rate of 10%, 216 patients had to be randomly assigned. This sample size calculation did not use the information from the 70 patients from the phase II part of the trial; instead, it was based on the reported PFS from J9511 trial [3] .
Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards model was used for estimation of hazard ratios (HRs). The survival analysis was carried out according to the intent-to-treat principle. All patients who received at least one dose of chemotherapy were assessable for toxicity. Figure 1 .
The baseline patient and disease characteristics are given in Table 2 . One-third of patients were female, 13% were older than 70 years, and 90% of patients in both arms had a Karnofsky performance status of 70%-100%. Twenty-five percent of patients had brain metastases at the time of enrollment (Table 2) . Table 4 . Hematologic toxicity was significantly higher in the EP arm. However, only a trend for a higher rate of febrile neutropenia was observed in the EP arm (7% versus 4% in the IP arm; P = 0.263). A total of seven treatment-related deaths occurred: three in the IP arm and four in the EP arm. In the IP arm, one patient who had received radiotherapy of a sacral spine metastasis developed toxic colitis with subsequent septic multiorgan failure; another patient developed fatal toxic colitis without receiving radiotherapy. All other drug-related deaths could be attributed to septic bacterial infections in grade 4 neutropenia. In the irinotecan arm, 11% and 3% of patients had grade 3 and 4 diarrhea, which was significantly higher than in the etoposide arm (5% grade III) (see Table 4 ).
efficacy analysis
There were no statistically significant differences in PFS and OS between both arms. Six-month PFS was 49.8% [95% confidence interval (CI) 39.6% to 51.0%] in the IP arm and 37.4% (95% CI 27.8% to 47.0%) in the EP arm, respectively. Median PFS was 6.0 months (95% CI 5.0-7.0) in the IP arm and 6.0 months (95% CI 5.2-6.8) in the EP arm (P = 0.07; log-rank test; HR EP versus IP = 1.29; 95% CI 0.96-1.73) (Figure 2 ). Median survival was 10.0 months (95% CI 8.4-11.6) in the IP arm and 9.0 months (95% CI 7.6-10.4) in the EP arm (P = 0.06; log-rank test; HR EP versus IP = 1.34; 95% CI CNS  31  29  23  21  Liver  36  34  48  44  Lung  28  26  43  39  Adrenal  21  20  21  19  Bone  29  27  31  28 IP, irinotecan + carboplatin; EP, etoposide + carboplatin; PS, performance status; CNS, central nervous system. Annals of Oncology original article 0.97-1.85) (Figure 3) . One-year PFS was 11.8% (95% CI 4.2% to 19.4%) in the IP arm and 6.5% (95% CI 1.1% to 11.9%) in the EP arm (P = 0.22). One-year survival was 37.1% (95% CI 26.1% to 48.1%) and 30.3% (95% CI 20.5% to 40.1%) in the IP and EP arms (P = 0.36), respectively. There was no difference in response rates (IP 54%, EP 52%) ( Table 5 ).
sensitivity analysis
After adjusting for center, which was the stratification factor for randomization, multivariate analysis revealed an HR for disease progression was 1.35 (95% CI 1.00-1.73; P = 0.095), whereas a significantly improved survival with an HR of 1.40 (95% CI 1.01-1.93; P = 0.043) was found.
additional treatment
After response or stabilization following first-line chemotherapy, 37 and 30 patients in the IP and EP arms received prophylactic cranial irradiation (P = 0.645, v 2 test). Second-and third-line treatments are listed in Table 6 . More patients in the EP arm received topotecan after progression on protocol treatment. Similarly, two North American and one international phase III trial reported earlier could not identify significant differences in efficacy between irinotecan and etoposide in combination with cisplatin [5] [6] [7] . Possible explanations could be attributed to differences in pharmacogenomics between the Asian and Caucasian populations as demonstrated for uridine diphosphate glucuronosyltransferase 1 (UGT1A1) [13] .
Nevertheless, a phase III trial from Scandinavia had demonstrated superior survival for irinotecan-carboplatin over oral etoposide-carboplatin in Caucasians [4] . This trial included a similar number of patients as our trial but investigated a higher dose intensity of irinotecan with 175 mg/m 2 every 3 weeks. This higher dose intensity might have contributed to the statistically significant advantage of irinotecan in terms of improved OS. In addition, dose intensity of irinotecan and etoposide was 92.2% and 97.4%, respectively, in our trial. This might also have contributed to the nonsignificant difference in survival results of our trial.
In addition, the sample size calculation of our trial was based on the relatively large difference in PFS at 6 months reported in J9511 trial [3] . Therefore, our trial might have been underpowered to detect a smaller difference between both drugs in Caucasians. Furthermore, the difference in cycle length of 4 weeks in the IP arm and 3 weeks in the EP arm also might have lead to an intrinsic bias of PFS detection in our study.
All randomized trials in SCLC showed a significantly higher frequency of diarrhea in the irinotecan arms as expected. Despite a detailed per protocol management scheme of diarrhea, 14% grade 3 or 4 diarrhea occurred in our trial, which is similar to the other trials reporting frequencies of 11%-20% [4] [5] [6] [7] [8] . One patient in our trial experienced fatal diarrhea with toxic colitis when concurrent radiotherapy of a bone lesion in the sacral spine was administered in addition to irinotecancarboplatin. Therefore, we strongly recommend not to carry out concurrent radiotherapy of bone metastases in the lower spine or pelvic region in any patient receiving irinotecan therapy. This had been prohibited during the ongoing trial by protocol amendment.
Hematologic toxicity was more favorable in the irinotecan arm of our trial without significant differences in febrile neutropenia. Hematologic toxicity in the EP arm of our trial was higher compared with the other trials because we administered a higher dose of etoposide (see Table 1 ). However, these results are in line with all other trials in which i.v. etoposide was used as standard treatment [3, [5] [6] [7] . The higher rate of severe diarrhea in the irinotecan arm weakens the advantage of a lower hematologic toxicity.
In conclusion, etoposide plus carboplatin or cisplatin remains standard treatment of ED SCLC. Nevertheless, differences in toxicity justify treatment of selected patients with irinotecan plus carboplatin. 
